Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Davis, Oxford
Ben Davis, Oxford GB
| Patent application number | Description | Published |
|---|---|---|
| 20100113549 | PYRROLIDINE COMPOUNDS - The present invention relates to a process for the preparation of a pyrrolidone compound of the formula (I): where R | 05-06-2010 |
Benjamin G. Davis, Oxford GB
| Patent application number | Description | Published |
|---|---|---|
| 20090181444 | MODIFIED CARBOHYDRATE PROCESSING ENZYME - A modified polypeptide having carbohydrate processing enzymatic activity is provided, said polypeptide comprising an amino acid sequence selected from: (a) the amino acid sequence of SEQ ID NO:2 comprising a mutation in at least one of W433, E432 and M439; (b) the amino acid sequence of an enzyme of glycosyl hydrolase family 1, comprising at least one mutation at an amino acid residue equivalent to W433, E432 or M439 of SEQ ID NO:2; and (c) a variant of (a) or (b) having carbohydrate processing enzymatic activity and comprising at least one amino acid mutation at a position equivalent to W433, E432 or M439 of SEQ ID NO:2. | 07-16-2009 |
Benjamin Guy Davis, Oxford GB
| Patent application number | Description | Published |
|---|---|---|
| 20080311048 | Imaging Agent - The invention provides a conjugate comprising an iron containing colloidal particle, the particle being conjugated to one or more sugar targeting moieties. The conjugate is useful as a contrast agent in medical imaging, particularly in magnetic resonance imaging (MRI). The agents of the present invention may cross the blood brain barrier and so may be particularly useful in the monitoring or diagnosis of conditions affecting the brain. | 12-18-2008 |
| 20100086958 | NOVEL ENZYME - Novel FDH enzymes are provided herein, including novel NADPH-specific and NADH-specific FDH enzymes. Additionally, methods are provided utilizing these novel enzymes in catalytic systems for in situ regeneration of NADPH or NADH. Further aspects of the invention relate to the definition and use of crystal structures of these novel enzymes. | 04-08-2010 |
| 20100092394 | Multimeric Particles - The invention provides multimeric particle comprising metal-containing particles covalently bonded to one another by linker groups wherein at least some of said linker groups are cleavable. The invention further provides a contrast agent comprising said multimeric particles, along with a method of improving contrast of an image using said contrast agent. | 04-15-2010 |
| 20110059501 | Protein Glycosylation - The present invention relates to methods for glycosylating a protein in which the protein is modified to include an alkyne and/or an azide group. The invention further relates to a protein glycosylated by these methods. | 03-10-2011 |
Peter David Davis, Oxford GB
| Patent application number | Description | Published |
|---|---|---|
| 20090202571 | Bioreductively-activated prodrugs - A compound of formula (1), or a pharmaceutically acceptable salt thereof, wherein: —Ar is a substituted heteroaryl group bearing at least one nitro or azido group or is a benzoquinone, naphthoquinone or fused heterocyloquinone; -R1 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl or optionally substituted heteroaryl; -R2 is a glycoside, OH, optionally substituted alkyl, optionally substituted alkoxy, C | 08-13-2009 |
Simon Davis, Oxford GB
| Patent application number | Description | Published |
|---|---|---|
| 20110086049 | Receptor Modulators - Method of identifying a modulator of CD28 comprising comparing a structural model of a candidate modulator with a structural model of CD28 to thereby determine whether the modulator will bind to CD28, wherein the structural model is derived from, or comprises, structural coordinates of a crystal of: (i) CD28, (ii) a fragment of CD28, or (iii) a homologue of (i) or (ii). The crystal of CD28 in a soluble form complexed with the Fab fragment of a mitogenic (superagonistic) antibody has been obtained and used for the determination of the 3D-structure of the receptor. The application also relates to modulators of superagonistic signalling for any receptor of the CD28 family, i.e. to superagonistic antibodies and chimeric proteins thereof, and to the screening of the superagonistic modulators. In the methods of screening, the binding of the candidate modulators to a portion of the receptor proximal to the cell membrane is investigated. | 04-14-2011 |
Susan Helen Davis, Oxford GB
| Patent application number | Description | Published |
|---|---|---|
| 20120040953 | Compounds for the Treatment of Metabolic Disorders - The present invention is directed to therapeutic compounds which have activity as agonists of GPR119 and are useful for the treatment of metabolic disorders including type II diabetes. | 02-16-2012 |